Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 9Unknown 1Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 13Lymphoid 4Thoracic 2Sarcoma 2Other hematologic neoplasm 2Genitourinary 2Gastrointestinal 2Head & Neck 1Dermatologic 1CNS 1Breast 1

Conditions

Melanoma 1

Interventions

pembrolizumab 58Cyclophosphamide 53Ipilimumab 52Nivolumab 44aldesleukin 35Interleukin-2 26fludarabine phosphate 22fludarabine 21Vemurafenib 20Temozolomide 19Radiotherapy 18dabrafenib 15trametinib 12Radiosurgery 11CTLA-4 Antigen 11Filgrastim 10Dacarbazine 10spartalizumab 9cobimetinib 9binimetinib 9atezolizumab 9Biopsy 9poly ICLC 8Paclitaxel 8Antilymphocyte Serum 8encorafenib 7avelumab 7Rituximab 7Introns 7romidepsin 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Thalidomide × Dermatologic × Clear all
NCT00505635 2020-09-24

Biochemotherapy With Temozolomide for Metastatic Melanoma

M.D. Anderson Cancer Center

Phase 2 Terminated
5 enrolled 5 charts
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡